Avax Technologies

Avax Technologies is a biotechnology company that specializes in the research and development of cancer vaccines. The company was founded in 1990 and is headquartered in Philadelphia, Pennsylvania. Avax Technologies is known for its innovative approach to cancer treatment, using autologous (self) cells to stimulate the body's immune system to fight cancer.

History

Avax Technologies was founded in 1990 with the aim of developing novel cancer treatments. The company's initial focus was on melanoma, a type of skin cancer, but it has since expanded its research to include other types of cancer.

Products and Services

Avax Technologies' main product is the M-Vax vaccine, which is used to treat patients with stage III and IV melanoma. The vaccine is made from the patient's own cancer cells, which are modified in the lab and then reintroduced into the patient's body to stimulate an immune response.

In addition to M-Vax, Avax Technologies also offers a range of other products and services, including AC Vaccine for the treatment of various types of solid tumors, and OVax, a vaccine for the treatment of ovarian cancer.

Research and Development

Avax Technologies is committed to ongoing research and development in the field of cancer vaccines. The company's research team is constantly working on new and innovative ways to stimulate the body's immune system to fight cancer.

See Also

• Biotechnology
• Cancer vaccine
• Melanoma
• Autologous